{"id":"NCT03097315","sponsor":"Clearside Biomedical, Inc.","briefTitle":"Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis","officialTitle":"Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-04","primaryCompletion":"2018-01-24","completion":"2018-01-24","firstPosted":"2017-03-31","resultsPosted":"2021-06-15","lastUpdate":"2021-06-23"},"enrollment":38,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Uveitis","Uveitis, Posterior","Uveitis, Anterior","Uveitis, Intermediate","Panuveitis"],"interventions":[{"type":"DRUG","name":"4 mg CLS-TA Suprachoriodal Injection","otherNames":["Triamcinolone Acetonide"]}],"arms":[{"label":"4 mg CLS-TA Suprachoriodal Injection","type":"EXPERIMENTAL"}],"summary":"This open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, CLS-TA, in patients with non-infectious uveitis with and without macular edema.","primaryOutcome":{"measure":"Adverse Events","timeFrame":"Baseline to 24 weeks","effectByArm":[{"arm":"4 mg CLS-TA Suprachoriodal Injection","deltaMin":27,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":["16196117","4000641","21220619","36787524","36399237"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":38},"commonTop":["Conjunctival haemorrhage","Intraocular pressure increased","Intraocular pressure increased","Eye pain","Procedure headache"]}}